Medpace Is Down 28%. What History Says About This Drop.

Medpace Is Up From Its Recent Lows. Here Is What History Says.

Medpace Holdings, Inc. (MEDP) has officially transitioned from the red zone to the yellow zone as of May 28, 2026, marking a critical shift in its 88-day drawdown. Our data shows that while the stock remains 27.8% below its all-time high of $620.59, the Drawdown Severity Score™ has improved to 4.9. This recovery mirrors a pattern we frequently observe in high-growth healthcare stocks, where extreme sell-offs often lead to prolonged consolidation periods in the "Significant" risk category before a full return to peak pricing.

The Path Out of the Red Zone

The recovery to a 4.9 Drawdown Severity Score™ indicates that the most acute selling pressure has subsided for Medpace Holdings, Inc. (MEDP). As of May 28, 2026, the stock is trading at $448.12, attempting to distance itself from the deeper losses seen earlier in this 88-day cycle. This transition out of the red zone is a statistical milestone that suggests the asset is moving from a state of "Extreme" distress into a "Significant" but more stable drawdown phase.

Our data shows that the current decline of 27.8% is far more severe than the company’s historical averages. Across 93 total historical drawdown events, the average maximum drawdown for Medpace Holdings, Inc. (MEDP) is only -7.0%. Furthermore, the average duration for a typical pullback is 34 days, a window that this current event has already exceeded by more than seven weeks.

Comparing the Recovery to Market Peers

When stocks exit the red zone and enter a Drawdown Severity Score™ of 4.9, they often face a "prove it" period. We have seen similar technical behavior in other mid-cap growth stocks like Paypal (PYPL) and Adobe (ADBE) during their respective recovery cycles. In those instances, moving into the yellow zone represented a floor in sentiment, though not necessarily an immediate rocket ship back to all-time highs.

For Medpace Holdings, Inc. (MEDP), the move to the yellow zone suggests that the market is beginning to digest the recent negative catalysts. While the stock is still down 27.8%, the stabilization of the severity score indicates that the "panic" phase of the sell-off has likely peaked. Investors typically use this yellow zone status to evaluate whether the underlying business fundamentals support a return to the green zone.

Historical Context and the 30% Threshold

History provides a sobering perspective on drawdowns of this magnitude for this ticker. Our data shows that Medpace Holdings, Inc. (MEDP) has dropped by 30% or more only 4 times in its trading history. This is a small sample size, which is a crucial caveat for any investor looking at historical averages.

In those 4 instances, the average duration of the comparable drops was 318 days. Given that the current drawdown has only lasted 88 days as of May 28, 2026, history suggests that recoveries from deep pullbacks in this specific stock can be lengthy processes. The jump from the red zone to the yellow zone is the first step, but the gap between the current price and the all-time high remains substantial.

News and Fundamental Catalysts

Several external factors have contributed to the volatility and the subsequent attempt at a rebound. According to PR Newswire, a shareholder class action was triggered following a 16% stock drop related to cancellation rates. This news created the "Extreme" severity environment that pushed the stock into the red zone initially.

Additionally, TIKR.com reported that the stock was down 32% from its 52-week high earlier in 2026, leading to a shift in valuation outlooks. More recently, GlobeNewswire issued a deadline alert for shareholders regarding legal proceedings. While legal headwinds often weigh on a stock, the current move to a 4.9 Drawdown Severity Score™ suggests that the market may have already priced in the bulk of these concerns.

The Distance to the Green Zone

To reach the green zone, Medpace Holdings, Inc. (MEDP) must continue to close the 27.8% gap to its all-time high of $620.59. The transition from a severity score of 4.9 back to a "Normal" or "Low" risk rating will require sustained price appreciation above the $500 level.

As of May 28, 2026, the data indicates that while the worst of the momentum-driven sell-off may be over, the stock is still in a "Significant" drawdown. Investors often monitor the Drawdown Severity Score™ during these periods to see if the stock can maintain its yellow zone status or if it risks a double-dip back into the red zone.